Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Don Miller who wrote (3781)	10/20/1999 1:12:00 PM
From: j_fir2	Respond to of 10280

Don, speaking as someone who has more experience in this area of medicine than I would like to have, yes, as a consumer, that throughout most of the 90's Prozac was the gold standard of antidepressants and certainly of the generation of a/d's called the SSRI's. But there is a newer generation of a/d's now, including Effexor, Celexa and maybe, say, Wellbutrin (to pick a few big names) that have preferable side-effect profiles than even the new-fangled SSRI's have. Also, in long term use, people and doctors are finding SSRI's less than desirable. There's something called the Prozac Poop-out--hate to say it, but that is what it is called--whereby Prozac and a lot of the SSRI's stop working their magic. I think historically a lot of a/d's _do_ have a way of not working after a while. My impression is, and maybe one of our M.D.s could step in here, that Prozac has had a really long run as a/d's go. But this phenomenon is one reason I'm glad Prozac II is generating other indications and is not, we hear, "just like Prozac only better." Jennifer